Merck and Moderna Initiate Phase 3 Trial Evaluating Adjuvant V940 (MRNA-4157) in Combination With KEYTRUDA (Pembrolizumab) After Neoadjuvant KEYTRUDA and Chemotherapy in Patients With Certain Types of Non-Small Cell Lung Cancer (NSCLC)
Express News | Merck and Moderna Initiate Phase 3 Trial Evaluating Adjuvant V940 (Mrna-4157) in Combination With Keytruda® (Pembrolizumab) After Neoadjuvant Keytruda and Chemotherapy in Patients With Certain Types of Non-Small Cell Lung Cancer (Nsclc)
Merck & Co., Inc. (MRK): Among the Best Dow Stocks to Buy According to Analysts
M&A Deals Roundup: Merck, Seadrill, Kraft Heinz, Spirit Airlines and More
About 75% of Companies That Reported Earnings This Week Delivered EPS Wins-Earnings Scorecard
Earnings Preview: Merck & Co to Report Financial Results Pre-market on October 31
$Merck & Co(MRK.US)$ is scheduled to release its financial results pre-market on October 31 ET. Earnings PreviewAnalysts estimate $Merck & Co(MRK.US)$ to post revenue of USD16.51B for 2024Q3, up 3.44%